ABSTRACT
Rationale & Objective The nasal passages harbor both commensal and pathogenic bacteria. In this study, we sought to characterize the anterior nasal microbiota in PD patients using 16S rRNA gene sequencing.
Study Design Cross-sectional.
Setting & Participants We recruited 32 PD patients, 37 kidney transplant (KTx) recipients, 22 living donor/healthy control (HC) participants and collected anterior nasal swabs at a single point in time.
Predictors We performed 16S rRNA gene sequencing of the V4-V5 hypervariable region to determine the nasal microbiota.
Outcomes Nasal microbiota profiles were determined at the genus level as well as the amplicon sequencing variant level.
Analytical Approach We compared nasal abundance of common genera among the 3 groups using Wilcoxon rank sum testing with Benjamini-Hochberg adjustment. DESeq2 was also utilized to compare the groups at the ASV levels.
Results In the entire cohort, the most abundant genera in the nasal microbiota included: Staphylococcus, Corynebacterium, Streptococcus, and Anaerococcus. Correlational analyses revealed a significant inverse relationship between the nasal abundance of Staphylococcus and that of Corynebacterium. PD patients have a higher nasal abundance of Streptococcus than KTx recipients and HC participants. PD patients have a more diverse representation of Staphylococcus and Streptococcus than KTx recipients and HC participants. PD patients who concurrently have or who developed future Staphylococcus peritonitis had a numerically higher nasal abundance of Staphylococcus than PD patients who did not develop Staphylococcus peritonitis.
Limitations 16S RNA gene sequencing provides taxonomic information to the genus level.
Conclusions We find a distinct nasal microbiota signature in PD patients compared to KTx recipients and HC participants. Given the potential relationship between the nasal pathogenic bacteria and infectious complications, further studies are needed to define the nasal microbiota associated with these infectious complications and to conduct studies on the manipulation of the nasal microbiota to prevent such complications.
Competing Interest Statement
DMD, JRL, and IDV hold patent US-2020-0048713-A1 titled, Methods of Detecting Cell-Free DNA in Biological Samples, licensed to Eurofins Viracor. LFW has received or receives research support from Accelerate Diagnostics, Inc., biomerieux, Inc., Hardy Diagnostics, and Roche Molecular Systems, Inc., and consulting fees from Roche Molecular Systems, Inc., Shionogi, Inc., and Talis Biomedical. MJS reports research support from Merck, Biomerieux, and SNIPRBiome, compensation for consulting from Shionogi, and compensation for participation in a Data and Safety Monitoring Board from AbbVie. CK is a consultant for Rebiotix/Ferring and on the Scientific Advisory Board of Seres Therapeutics. DMD serves as a consultant for CareDx and is a site clinical investigator for studies sponsored by AlloVir and CSL Behring. JS is the Co-Chair of the American Society of Nephrology Workgroup on COVID-19 and other Emerging Threats and of the American Society of Nephrology Emergency Partnership Initiative and has received consulting fees from Alkahest, Bayer, Honeywell, Kaneka and St. Gobain. IDV is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX. VS reports receiving speakers fees from Baxter Healthcare. JRL received research support under an investigator-initiated research grant from BioFire Diagnostics, LLC. JRL receives speakers fees from Astellas.
Funding Statement
This study was supported in part by R21AI164093 (JRL, IDW).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Weill Cornell Institutional Review Board approved this protocol (IRB # 1604017181) and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding. This study was supported in part by R21AI164093 (JRL, IDW).
Financial Disclosure. DMD, JRL, and IDV hold patent US-2020-0048713-A1 titled “Methods of Detecting Cell-Free DNA in Biological Samples” licensed to Eurofins Viracor. LFW has received or receives research support from Accelerate Diagnostics, Inc., bioMérieux, Inc., Hardy Diagnostics, and Roche Molecular Systems, Inc., and consulting fees from Roche Molecular Systems, Inc., Shionogi, Inc., and Talis Biomedical. MJS reports research support from Merck, Biomérieux, and SNIPRBiome, compensation for consulting from Shionogi, and compensation for participation in a Data and Safety Monitoring Board from AbbVie. CK is a consultant for Rebiotix/Ferring and on the Scientific Advisory Board of Seres Therapeutics. DMD serves as a consultant for CareDx and is a site clinical investigator for studies sponsored by AlloVir and CSL Behring. JS is the Co-Chair of the American Society of Nephrology Workgroup on COVID-19 and other Emerging Threats and of the American Society of Nephrology Emergency Partnership Initiative and has received consulting fees from Alkahest, Bayer, Honeywell, Kaneka and St. Gobain. IDV is a member of the Scientific Advisory Board of Karius Inc., Kanvas Biosciences and GenDX. VS reports receiving speakers’ fees from Baxter Healthcare. JRL received research support under an investigator-initiated research grant from BioFire Diagnostics, LLC. JRL receives speakers’ fees from Astellas.
Data Availability
Sequencing data that support the findings of this study will be made available in the database of Genotypes and Phenotypes (dbGaP) phs002251.v1.p1 after peer-reviewed acceptance. Local institutional review board approval will be needed to access the data.
